Periplasmic expression and one-step purification of urease subunit B of Helicobacter pylori by Alvandi, Amirhooshang et al.
ORIGINAL PAPER
Periplasmic expression and one-step purification of urease subunit
B of Helicobacter pylori
Amirhooshang Alvandi • Ahmad Farajzadeh • Mehri Ghaforian Borojerdnia •
Abbass Jelodar • Ehsan Aryan • Abolfazl Gholipour •
Abdolrahim Masjedizadeh • Manoochehr Makvandi
Received: 28 April 2010 / Accepted: 13 August 2010 / Published online: 27 August 2010
 Springer Science+Business Media B.V. 2010
Abstract UreB is one of the urease subunits of Helico-
bacter pylori and can be used as an excellent antigen
candidate for H. pylori vaccination. Easy access to highly
purified UreB protein, facilitate advances in therapeutic or
preventive strategies. To achieve a simplified purification
procedure, the present report represents a novel method of
producing recombinant urease subunit B extracellularly.
ureB gene from 26,695 standard strain was amplified by
PCR and cloned into pET-26b(?) expression vector. UreB
was expressed as a soluble, N-terminal pelB and C-termi-
nal hexahistidine-tagged fusion protein (UreB-6His) and
secreted into the periplasmic space of Escherichia coli.
Expression of the recombinant UreB in E. coli BL21 (DE3)
was induced by isopropylthio-b-D-galactoside (IPTG).
Expression of UreB was confirmed by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE)
and western blot analysis using anti-His monoclonal anti-
body. UreB-6His protein was extracted from the periplasm
by osmotic shock treatment and was purified in one step by
Nickel affinity chromatography. In conclusion, the present
protocol is easier to perform; more time effective and low
cost than earlier methods.
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Introduction
Helicobacter pylori causes peptic ulcer disease and some
forms of gastric cancer. It is one of the most common
chronic bacterial infections of humans (Hatzifoti et al.
2000). The most efficient and economical approach with
low risk of adverse reaction to the prevention and control
of H. pylori infection is vaccination (Del Giudice and
Michetti 2004; Rupnow et al. 1999).
Urease and its subunits are currently the most promising
vaccine candidates, and their value as vaccine antigens
have been confirmed by numerous studies in mice, ferrets,
non-human primates and human clinical trials (Cuenca
et al. 1996; Del Giudice and Michetti 2004; Ferrero et al.
1994; Haas and Meyer 1997; Stadtlander et al. 1996). UreB
one of the four subunits of urease produced by almost all
the isolated strains of H. pylori. It has been demonstrated to
have the strongest antigenicity in all known proteins of
H. pylori (Corthesy-Theulaz et al. 1995; Pappo et al. 1995).
ureB gene, responsible for encoding UreB with 569 amino
acid residues, is a highly conserved nucleotide sequence
with a similarity of approximately 95% in different
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H. pylori isolates (Akada et al. 2000; Labigne et al. 1991).
On the other hand, it has been proven that UreB is more
protective and safer than subunit A in mice; with no signs
of gastritis or other side effects after therapeutic vaccina-
tion (Corthesy-Theulaz et al. 1995; Ferrero et al. 1995;
Hatzifoti et al. 2004). These data strongly indicate that
UreB can be used as an excellent antigen candidate for
vaccination against H. pylori.
Easy access to highly purified UreB protein by investi-
gators should therefore facilitate advances in therapeutic
or preventive strategies. Previous purification methods of
native or recombinant urease and its subunits invariably
required two or several steps involving conventional size
exclusion and cation exchange or FPLC combining cation
exchange, size exclusion chromatography, and sometimes
the conventional hydrophobic interaction gel (Evans et al.
1991; Turbett et al. 1992).
Recovery of a recombinant gene product can be greatly
simplified by a secretion strategy that minimises contami-
nation from host proteins and even in the case of peri-
plasmic translocation, a simple osmotic shock or cell wall
permeabilization can be used to obtain the product without
the release of cytoplasmic protein contaminants. In addi-
tion secretion of recombinant proteins to the periplasmic
space of E. coli by fusing a signal peptide to the N-terminal
residue, have several advantages such as reduction of
contamination with endotoxins and DNA, higher product
stability, solubility and biological activity and correct
folding (Baneyx and Mujacic 2004; Cornelis 2000; Merg-
ulhao et al. 2005; Rastgar Jazii et al. 2007; Shokri et al.
2003). Periplasmic expression has been shown to be ben-
eficial in the production of several recombinant proteins.
In order to simplify the procedure steps and further
reduce cost in H. pylori vaccine production, the present
report represents a novel method of producing recombinant
Urease subunit B extracellularly. This method is based on
expression of UreB sequence containing a NH2-terminal
pelB signal peptide in E. coli. Therefore periplasmic con-
tent is released from the bacterial pellet by a simple EDTA-
containing buffer and the protein can be chromatographed
in a single step by affinity chromatography.
Materials and methods
Bacteria and culture conditions
H. pylori strain 26,695 was used in this study grown on
Brucella agar supplemented with 10% (v/v) defibrinated
sheep blood, containing vancomycin (10 lg ml-1), tri-
methoprim (5 lg ml-1) and amphotericin B (2 lg ml-1) at
37C under microaerophilic conditions for 3 days. E. coli
DH5a was grown at 37C in Luria-Bertani medium
(Invitrogen, USA) used for molecular biology manipula-
tions and for maintenance of recombinant plasmid DNA.
E. coli BL21 (DE3) (Novagen, USA) was used for 6-His-
tagged fusion peptide expression was grown at 37C in LB
medium.
Designing of primers
ureB nucleotide sequence of H. pylori strain 26,695
(GenBank accession number AF507994) was retrieved
from the NCBI GenBank (NCBI). Primers were designed
with restriction enzyme sites using DNASIS 2.6 software.
The stop codon was excluded in designing the reverse
primer.
Construction of expression vector
Whole-cell DNA from H. pylori strain 26,695 was
extracted by Genomic Extraction Kit (MBI Fermentas,
Lithuania) according to the manufacture’s procedure. ureB
was amplified by the PCR using the following oligonu-
cleotides (Cinagene, Iran): 50-CAT GCC ATG GCA TGG
AAA AAG ATT AGC AGA AAA G-30 (forward) and 50-
CCG CTC GAG CGG GAA AAT GCT AAA GAG TTG
CG-30 (reverse). The underlined bases designate NcoI and
XhoI restriction sites. PCR was performed using Expand
High Fidelity PCR System (Roche, Germany) following
the manufacturer’s protocol. PCR product fragment was
electrophoresed on the 1% agarose gel stained with ethi-
dium bromide. Subsequently the PCR product was purified
using the DNA Extraction kit (MBI Fermentas, Lithuania)
and double digested with NcoI and XhoI. The double
digested PCR product was ligated into pET-26b(?), which
was digested with the same restriction enzymes to form the
over-expression plasmid pET26b-UreB. The ligated plas-
mids were transformed into the competent E. coli DH5a
and transformants were selected on LB medium containing
kanamycin (50 mg l-1). The presence of inserts was con-
firmed by colony PCR. Correct orientation and the com-
plete insert sequence were verified by restriction digestion
analysis using PvuI and sequencing (TAG Copenhagen,
Denmark).
Expression of fusion protein
The pET26b-UreB transformed into the expression host
E. coli BL21(DE3). To evaluate protein expression a single
colony was inoculated into 10 ml of terrific broth con-
taining kanamycin (50 mg l-1) and grown at 37C over-
night. This preculture was then added to 500 ml of the
same medium which was incubated on a shaker (200 rpm)
at 37C until the optical density (O.D. 600 nm) of culture
reached up to 0.6. Bacterial cultures were induced using
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different concentrations of isopropyl thiogalactoside
(IPTG) 0.1–1.0 mM and the culture incubated in 22C or
37C. 1.5 ml bacterial culture was harvested every 1 h up
to 8 h. Similarly, the E. coli BL21 containing pET-26b was
induced up to 8 h as a negative control. Expression of
protein was analyzed by sodium dodecyl sulphate–poly-
acrylamide gel electrophoresis (SDS–PAGE) under dena-
turing conditions. For purification of the recombinant
protein, the E. coli culture was grown using the optimized
expression conditions (Terrefic Broth medium, 22C,
1 mM IPTG, 4 h of induction). The bacteria were har-
vested by centrifugation at 4C.
Preparation of the periplasmic extract
Osmotic shock was applied according to the Neu and
Heppel (1965), with modifications. Cell pellets were
resuspended in ice-cold buffer A (0.03 M Tris–HCl, pH
7.3), and harvested by centrifugation at 5,000 rpm (5804R
centrifuge, rotor # A-4-44, Eppendorf) for 10 min at 4C.
The pellets were suspended in 40 ml buffer A plus 40 ml
ice-cold buffer B [0.3 M Tris–HCl pH 8.0, 1.5 mM EDTA,
40% (w/v) sucrose] for each gram wet weight of cells and
was shaken for 30 min on ice. Following centrifugation,
the pellet was rapidly resuspended in the same volume of
cold water and the suspension shaken for 30 min on ice and
then centrifuged again for 10 min. The supernatant
(osmotic shock fluid) was collected as the periplasmic
fraction.
Purification of recombinant UreB
Recombinant UreB was purified from the periplasm using a
published protocol (Loo et al. 2002) with some modifica-
tions. Briefly, the periplasmic fraction was adjusted to pH 7
using Mops (Sigma, Germany) to produce a final concen-
tration of 20 mM. The sample was then loaded onto a
column containing 10 ml Ni-NTA agarose (nickel-nitrilo-
triacetic acid) (Qiagen, France), pre-equilibrated with
chromatography buffer (20 mM Mops, 0.5 M NaCl, 5 mM
imidazole, pH 8.0) and rocked for 3 h. The column was
washed with chromatography buffer until the absorbance of
the eluate returned to baseline. Recombinant UreB was
eluted with a 20 ml 500 mM imidazole in chromatography
buffer. Peak fractions were identified by SDS–PAGE.
Positive fractions were pooled and dialyzed against PBS
buffer at 4C overnight. Protein concentration was mea-
sured by a Bradford assay based on a bovine serum albu-
min standard curve (Bradford 1976). To determine that
periplasmic UreB was not contaminated by cytoplasmic
proteins, presence of b-Galactosidase in osmotic shock
and cytoplasmic fractions was compared. b-Galactosi-
dase assays were performed using o-nitrophenyl-b-D-
galactopyranoside (ONGP) as a substrate, as described by
Miller (1972).
SDS–PAGE and immunobloting
The resulting bacterial pellet or purified protein were
homogenized in SDS sample loading buffer [0.150 M
Tris–Cl, pH 6.8; 10% glycerol; 2% SDS; 0.01% bromo-
phenol blue; 0.5 M DTT (Dithiothreitol)]. It was mixed
properly and boiled for 5 min and centrifuged at
11,000g for 2 min. Electrophoresis was performed in the
presence of SDS according to the method of Laemmli
(1970). The discontinuous gel consisted of a 5% stacking
gel and a 10% separating gel which was run on a vertical
electrophoresis unit (Mini-Protean II, BioRad). After SDS–
PAGE gel was transferred onto nitrocellulose membrane by
Bio-Rad Mini Trans-Blot Cell system following the pro-
cedure described. Membrane was blocked using 3% nonfat
dry milk in TTBS (50 mM Tris–HCl, pH 7.5, 150 mM
NaCl, 1% Tween 20) for 1 h. Following four washes the
membrane was dipped into 1:4,000 diluted monoclonal
antibody conjugated proxidase anti-His for 1.5 h at room
temperature. BM Blue POD substrate precipitating (Roche,
Germany) was used to develop the membrane, until dark
purple bands appear, following the procedure described
(Sambrook and Russell 2001).
Results
Construction of plasmid for periplasmic expression
of UreB
To overcome problems associated with cytoplasmic
expression of UreB (Evans et al. 1991; Icatlo et al. 1998;
Lee et al. 1995), an expression vector for periplasmic
expression of UreB was constructed. The full-length ureB
gene without stop codon was amplified by primers which
contains restriction sites. NcoI and XhoI restriction sites
were introduced upstream and downstream of the ureB
gene respectively, therefore the coding sequence was pre-
ceded by a pelB signal sequence at the 50 region and a
6His-tag at the 30 of the gene. The target fragment of ureB
genes with the expected sizes are shown in Fig. 1.
Construct transformed into E. coli DH5-a cells and
selected on LB containing kanamaycin (50 mg l-1).
Transformants were characterized by colony PCR against
ureB primers. The recombinant pET26b-UreB was
extracted and its orientation confirmed by digestion with
PvuI restriction enzyme. PvuI will have two restriction
sites in recombinant plasmid, one in insert and the other
one in vector. The two expected bands were observed on
gel: a 1585–5442 bp bands (Fig. 2). Sequence analysis of
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recombinant pET26b-UreB confirmed that there are no
amplification errors and that cloning was accurate.
Overexpression and purification of UreB
The pET26b-UreB was transformed into the expression
host E. coli BL21 (DE3). Transformant was grown at dif-
ferent temperatures, and expression was induced by IPTG
and monitored by SDS–PAGE of total protein extracts
before and after induction. Highest levels of over-expres-
sed UreB were obtained by allowing the bacterial cultures
to grow to an OD 600 nm of 0.6–0.8 before induction and
by inducing protein production for 4 h at 25C with 1 mM
IPTG. OD600 at harvest was 5.0 and the cell wet weight
after harvest was 4 g l-1. The cell fractionation analysis
showed that the UreB was mostly detected in the soluble
fraction. Figures 3 and 4 show the protein profiles in non-
induced and induced bacteria, periplasmic content and
purified UreB-6His tag protein by Ni-NTA affinity
Fig. 1 Target amplification fragment of ureB gene and NcoI and
XhoI double digested ureB PCR product. Lane 1, Lambda DNA/
EcoRI ? HindIII Marker; Lane 2, Target recovered fragment of ureB
gene (1731 bp); Lane 3, Target recovered fragment ureB after
digestion with both NcoI and XhoI (1722 bp)
Fig. 2 Agarose gel electrophoresis analysis of recombinant pET26b-
UreB with PvuI restriction enzyme digestion. Lane 1 Lambda DNA/
EcoRI?HindIII Marker, Lane 2 pET26b-UreB recombinant plas-
mid (white arrow, 7027 bp), Lane 3 PvuI digested recombinant
pET26b-UreB. Two expected fragments were observed on the gel
(5442–1585 bp bands)
Fig. 3 SDS–PAGE analysis of the control negative bacteria (E. coli
BL21 with pET21 without insert) (a) and the expressed UreB-6His
tag protein in E. coli BL21 (b). A 15 ll volume of each fractions were
analyzed by 10% polyacrylamide gel. a Lane 1, PageRulerTM
Unstained Protein Ladder; lane 2, total cell lysate of noninduced
bacteria; lane 3–6, Total cell lysate of bacteria after 1–4 h induction;
lane 7, total cell lysate of noninduced control negative E. coli BL21;
lane 8–10, total cell lysate of induced control negative E. coli BL21
after 1–3 h induction b Lane 1, PageRulerTM Prestained Protein
Ladder; lane 2, total cell lysate of noninduced bacteria; lane 3. Total
cell lysate of bacteria after 4 h induction; lane 4, periplasmic proteins
extracted by osmotic shock procedure; lane 5, purified periplasmic
UreB-6His by Ni-NTA agarose. The arrow indicates the position of
UreB-6His on the gel
Fig. 4 Western blot analysis of the expressed UreB-6His tag protein
in E. coli BL21. A 15 ll volume of each fractions were analyzed by
10% polyacrylamide gel and transferred onto nitrocellulose mem-
branes and revealed with an anti-His monoclonal antibody. Lane 1,
PageRulerTM Prestained Protein Ladder; lane 2, total cell lysate of
noninduced bacteria; lane 3. Total cell lysate of bacteria after 4 h
induction; lane 4, periplasmic proteins extracted by osmotic shock
procedure; lane 5, purified periplasmic UreB-6His by Ni-NTA
agarose. The arrow indicates the position of UreB-6His on the
membrane
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chromatography by SDS–PAGE and Western blot analy-
ses. As shown in these figures a protein band migrating to
the expected molecular weight for a UreB-6His-tag protein
(&65 kDa) was clearly detected in the induced cells after
4 h and periplasmic fraction extracted by osmotic shock
procedure. The yield of purified UreB was about 0.5 mg l-1
of culture media.
To prevent release of cytoplasmic content into the
periplasmic fraction during extraction (Malik et al. 2007),
the purification procedure was carried out within one day at
4C and in the presence of protease inhibitors. The small
quantity of b-galactosidase activity detected in the recov-
ery solutions from osmotic shock (less than 2% of cyto-
plasmic content) (data not shown) indicates that little
cytoplasmic material is released by this procedure.
Discussion
Currently H. pylori is recognized as the most widespread
human pathogen and approximately half of the world’s
population is infected (Czinn 2005; Rossi et al. 2004).
There is great interest in developing a vaccination method
to prevent H. pylori infection, given that immunization is
always considered the most economic and efficient means
for such prevention, especially in developing countries
(Del Giudice and Michetti 2004; Rupnow et al. 1999).
The selection of antigenic targets is critical in the design
of a H. pylori vaccine. A large number of published data
showed that UreB might be the most definitive antigen
candidate for H. pylori vaccine (Corthesy-Theulaz et al.
1995; Morihara et al. 2008; Pappo et al. 1995; Zhao et al.
2007). In order to simplify the procedure steps and further
reduce cost in H. pylori vaccine production, the present
report represents a novel method of producing recombinant
urease subunit B extracellularly.
As E. coli does not naturally secrete high amounts of
proteins (Sandkvist and Bagdasarian 1996), recovery of a
recombinant gene product can be greatly simplified by a
secretion strategy that minimises contamination from host
proteins. Additionally, if the product is secreted to the
culture medium, cell disruption is not required for recovery
and even in the case of periplasmic translocation, a simple
osmotic shock can be used to obtain the product without the
release of cytoplasmic protein contaminants (Mergulhao
et al. 2005; Shokri et al. 2003). The pET-26b vector pro-
duces recombinant protein with signal peptide pelB at the
N-terminal for periplasmic secretion and a His-tag at the
C-terminal for detection and purification. Therefore,
H. pylori UreB has been cloned into pET-26b, which places
protein over-expression under the control of a lac promoter
that is inducible with IPTG. Recombinant UreB-6His has
been purified by using a single chromatography step. In this
study the possibility of nonspecific exposure of cytoplasmic
proteins has been ruled out by comparing periplasm b-gal
activity to cytoplasm of E. coli transformed with pET26b-
UreB-6His. The yield of purified UreB is lower than that in
some cytosolic expression systems, however, considering
the ease and low costs of scaling up a periplasmic proce-
dure, the protocol can be regarded to be productive. In
future the yield of the UreB protein could strongly be
increased by use of different signal sequences of prokary-
otic origin and optimizing the fermentation process. In
conclusion, the present protocol is easier to perform; more
time effective and low cost than earlier methods.
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